

Research Article

Bromo-enol Lactone, an Inhibitor of Calcium-Independent Phospholipase A₂, Suppresses Carrageenan-Induced Prostaglandin Production and Hyperalgesia in Rat Hind Paw

Keiichiro Tsuchida,¹ Takae Ibuki,¹ and Kiyoshi Matsumura²

¹Department of Anesthesiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kamigyo-ku, Kyoto 602-8566, Japan

²Department of Biomedical Engineering, Osaka Institute of Technology, Asahi-ku, Osaka 535-8585, Japan

Correspondence should be addressed to Kiyoshi Matsumura; kiyoshi.matsumura@oit.ac.jp

Received 12 January 2015; Revised 4 April 2015; Accepted 15 April 2015

Academic Editor: Vinod K. Mishra

Copyright © 2015 Keiichiro Tsuchida et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Prostaglandin (PG) E₂ and PGI₂ are essential to hyperalgesia in inflammatory tissues. These prostaglandins are produced from arachidonic acid, which is cleaved from membrane phospholipids by the action of phospholipase A₂ (PLA₂). Which isozyme of PLA₂ is responsible for the cleavage of arachidonic acid and the production of prostaglandins essential to inflammation-induced hyperalgesia is not clear. In this study, we examined the effects of two PLA₂ isozyme-specific inhibitors on carrageenan-induced production of PGE₂ and PGI₂ in rat hind paw and behavioral nociceptive response to radiant heat. Local administration of bromo-enol lactone (BEL), an inhibitor of calcium-independent PLA₂ (iPLA₂), significantly reduced carrageenan-induced elevation of prostaglandins in the inflamed foot pad 3 h after injection. It also ameliorated the hyperalgesic response between 1 h and 3 h after carrageenan injection. On the other hand, AACOCF₃, an inhibitor of cytosolic PLA₂, suppressed neither prostaglandin production nor the hyperalgesic response. BEL did not suppress the mRNA levels of iPLA₂β, iPLA₂γ, cyclooxygenase-2, microsomal prostaglandin E synthase, prostaglandin I synthase, or proinflammatory cytokines in the inflamed foot pad, indicating that BEL did not suppress inflammation itself. These results suggest that iPLA₂ is involved in the production of prostaglandins and hyperalgesia at the inflammatory loci.

1. Introduction

Acute inflammation produces a condition known as hyperalgesia, which is characterized by enhanced pain sensation and reduced pain threshold. This abnormal sensory state is brought about, at least in part, by sensitization of peripheral nociceptors. Accumulating evidence indicates that inflammatory mediators including prostaglandin E₂ (PGE₂) and PGI₂ are responsible for the sensitization of nociceptors [1, 2]. Recent studies further clarified the molecular mechanism of sensitization: PGE₂ and PGI₂ enhance or sensitize the activity of the capsaicin receptor transient potential receptor V1 (TRPV1) through the activation of PGE₂ EP1 and PGI₂ receptors, respectively [3]. Protein kinase C and protein kinase A are involved in the activation of TRPV1 by these

prostaglandins. In contrast, cyclopentenone prostaglandins, including 15-d-PGJ₂, PGA₂, and PGA₁, which are metabolites of PGD₂, PGE₂, and PGE₁, respectively, directly activate the irritant receptor TRPA1 [4]. For pharmacological control of inflammatory hyperalgesia, it is important to understand how these prostaglandins are produced in inflamed tissues.

Prostaglandins are generated through the arachidonic acid cascade [5], which involves three enzymatic steps: first phospholipase A₂ (PLA₂) cleaves membrane phospholipids and releases arachidonic acid; second, cyclooxygenase (COX) converts arachidonic acid into PGH₂; and, third, various types of prostaglandin isomerases convert PGH₂ to bioactive prostaglandins, including PGE₂ and PGI₂. Each enzymatic reaction can involve multiple isozymes. Recent studies have shown that COX-2, an inducible isozyme of

COX, and microsomal prostaglandin synthase-1 (mPGES-1), an inducible isozyme of PGE synthase, are responsible for the generation of PGE₂ in inflamed tissues [6, 7]. In these studies, administration of a COX-2 inhibitor to rats [7] or disruption of the mPGES-1 gene in mice lowered PGE₂ content in inflamed tissues and eased pain-related behaviors [6]. Thus, COX-2 and mPGES-1 could be pharmacological targets for the treatment of inflammatory pain.

However, it is not clear which isozyme of PLA₂ is responsible for the production of prostaglandins and development of hyperalgesia in inflamed tissues. PLA₂ has over ten isozymes which are classified into three categories based on their structural and functional similarities [8, 9]. First, cytosolic PLA₂s (cPLA₂ or group IV PLA₂) are located in the cytoplasm and are activated by low calcium ion concentrations (μ M levels). Second, secretory PLA₂s (sPLA₂ or group IB, II, V, or X PLA₂) are released into the extracellular space where they are activated by high concentrations (mM levels) of calcium ions. Third, calcium-independent PLA₂s (iPLA₂ or group VI PLA₂) are present in the cytoplasm and do not require calcium ions for their enzymatic activity, although the precise mechanisms for activation are unclear. Among these PLA₂s, a significant role for iPLA₂ in the production of prostaglandins in carrageenan-induced pleuritis in rats was demonstrated [10]. It is also reported that, in the spinal cord, cPLA₂ seems to be involved in inflammation-induced hyperalgesia [11]. In the present study, we examined if iPLA₂ and/or cPLA₂ are responsible for the production of prostaglandins and development of hyperalgesia in carrageenan-induced inflammation in the rat hind paw.

2. Materials and Methods

2.1. Materials. Male Sprague-Dawley rats (nine weeks old, 300–320 g) were purchased from Charles River Laboratories (Yokohama, Japan). All chemicals were obtained from commercial suppliers: bromoenol lactone (BEL; iPLA₂ inhibitor), arachidonyl trifluoromethyl ketone (AACOCF₃; cPLA₂ inhibitor), PGE₂ enzyme immunoassay (EIA) kit, and 6-keto-PGF_{1 α} EIA kit from Cayman Chemical (Ann Arbor, MI); Isogen (RNA extraction solution) from Nippon Gene (Tokyo, Japan); reverse transcription Kit from Invitrogen (Carlsbad, CA); PCR Sybr Green master mix, LightCycler TaqMan Master, and TaqMan Probes from Roche Diagnostics (Indianapolis, IN); and RNAlater (RNA stabilization solution) from Ambion (Austin, TX).

2.2. Animals. All experiments were carried out according to protocols approved by the Institutional Animal Care Committee of Kyoto Prefectural University of Medicine. Rats were housed four per cage and maintained on a 12 h light/dark cycle (light on 8:00–20:00) with controlled temperature ($25 \pm 3^\circ\text{C}$) and humidity ($55 \pm 15\%$). Animals were allowed free access to food and water at all times.

2.3. Pharmacological Treatment. The plantar surface of the left paw received a subcutaneous injection of either 3 mg type λ carrageenan (Sigma-Aldrich, St. Louis, MO) dissolved in

100 μ L saline or saline alone. Just after carrageenan injection, one of the two PLA₂ inhibitors (30 nmol) or vehicle (100 μ L of 0.1% dimethyl sulfoxide (DMSO) in saline) was injected into the same site. The inhibitor dose was determined according to the study by Gilroy et al. [10]. For biochemical analyses, each rat was anesthetized with pentobarbital (60 mg/kg, intraperitoneal injection) 3 h after subcutaneous injection, and the left hind leg was cut at the knee, quickly frozen in dry ice powder, and kept at -80°C until further processing. Rats were killed by decapitation. This time point was determined based on the following nociceptive behavior study, in which a PLA₂ inhibitor was effective between 1 h and 3 h after injection.

For the assessment of nociceptive behavior response, rats were injected with the carrageenan/saline and PLA₂ inhibitors/vehicle in the manner described above. Thermally evoked paw-withdrawal response was assessed using a device developed in Yaksh's lab [12]. The paw-withdrawal latency was measured for the left hind paw before and every 60 minutes after the subcutaneous injection for a total of 360 minutes. For each time point, the latencies were measured 3 times in each rat and averaged. Paw-withdrawal latencies were expressed as ratios to the baseline value of each rat.

2.4. Biochemical Assay. For analyses of PGE₂ and 6-keto-PGF_{1 α} (a metabolite of PGI₂), the hind paws were coronally cut into 50 μ m thick frozen sections in a cryostat at -20°C . Twenty of these sections were collected in a plastic tube containing precooled ethanol (1 mL) and indomethacin (10 μ g) which prevents the synthesis of prostaglandins during tissue processing. After measuring wet tissue weight, the sections were homogenized with polytron for 30 s followed by sonication for 20 s. The homogenates were centrifuged (15000 rpm for 20 min at 4°C) and the supernatant was collected. Ethanol was evaporated from the supernatant using a vacuum centrifuge. Prostaglandins, which were retained in the tube, were dissolved in EIA buffer. PGE₂ and 6-keto-PGF_{1 α} were measured using EIA kits according to the manufacturer's instructions. Tissue pellet remaining in the plastic tube was heated in a heat block to completely evaporate the ethanol. The weight of dried pellet was considered to be the dry tissue weight of the paw from which the prostaglandins were extracted.

2.5. Real-Time RT-PCR. Frozen paw sections were prepared as described above. Twenty of these sections were placed into a vial containing RNA later (1 mL) and stored at -30°C until further processing. For RNA extraction, the samples were homogenized in 1 mL phenol-based RNA extraction solution (Isogen) with polytron for 30 s followed by sonication for 20 s. Total RNA was isolated according to the manufacturer's instructions. cDNA was prepared from total RNA using M-MLV reverse transcriptase and random hexamer as the primer. The reverse-transcribed cDNA was amplified using a light cycler (Roche Diagnostics). mRNAs of COX-2, mPGES-1, iPLA_{2 β} , iPLA_{2 γ} , and GAPDH were quantified with the Sybr Green protocol. For the quantification of mRNAs of prostaglandin I synthase (PGIS), interleukin-1 β (IL1 β), and

interleukin-6 (IL6), the TaqMan Probe protocol was used. Primer pairs used for the PCR reaction were as follows:

COX-2: 5'-ctcactttgagtcattc-3', 5'-gattagtactgtagggtt-aatg-3',
 mPGES-1: 5'-aatgaaccacgcattcgct-3', 5'-cagccttca-tggtccgctc-3',
 iPLA₂β: 5'-caaggaactgggcaagatgg-3', 5'-agagggcgt-tgaccagcact-3',
 iPLA₂γ: 5'-gaataccacaacatacacga-3', 5'-acctaaaatag-tgtcagca-3',
 GAPDH: 5'-tgaacgggaagctcactgg-3', 5'-tccaccaccctg-ttctgta-3',
 PGIS: 5'-atgccatcaacagcatcaaa-3', 5'-gctccaggtcga-aatgagtc-3', TaqMan Probe (UPL #18),
 IL1β: 5'-tgtgatgaaagacggcacac-3', 5'-cttcttcttgggta-ttgtttg-3', TaqMan Probe (UPL #78),
 IL6: 5'-cccttcaggaacagcatgaa-3', 5'-acaacatcagtccca-agaag-3', TaqMan Probe (UPL #20),
 GAPDH: 5'-agctggtcatcaatgggaaa-3', 5'-attgatgtag-cgggatcg-3', TaqMan Probe (UPL #9).

Relative expression levels of each gene were calculated with the following formula:

$$\begin{aligned} & \text{Relative expression of mRNA} \\ & = \frac{2^{\text{cycle number of GAPDH}}}{2^{\text{cycle number of gene of interest}}} \end{aligned} \quad (1)$$

Specificity of the PCR products was checked by the melting curve and by agarose gel electrophoresis in the Sybr Green protocol.

2.6. Statistics. The significance of differences between two groups was determined by *t*-test. The significance of differences among multiple groups was determined by multiple *t*-tests with Bonferroni correction. Differences were considered significant at $P < 0.05$. Data are presented as mean \pm SEM.

3. Results

We examined the effects of PLA₂ inhibitors on PGE₂ and 6-keto-PGF_{1α} (a metabolite of PGI₂) levels in inflamed foot pad. Carrageenan and PLA₂ inhibitors/vehicle were injected into the right foot pad at the same time. Three hours after the injection, carrageenan significantly elevated PGE₂ and 6-keto-PGF_{1α} levels compared to injection of saline alone in vehicle-, BEL- and AACOCF₃-coinjected groups ($N = 4$ in each group, $P = 0.0002$ – 0.014) (Figure 1). BEL, an iPLA₂ inhibitor, significantly suppressed carrageenan-induced increases in PGE₂ by 57% ($P = 0.009$) and 6-keto-PGF_{1α} by 49% ($P = 0.017$) compared to vehicle. On the other hand, AACOCF₃, a cPLA₂ inhibitor and less potent iPLA₂ inhibitor, did not suppress the prostaglandin levels compared to the vehicle-treated rats. The two inhibitors did not exert significant effects on the prostaglandin levels in the saline-injected foot pad.

Real-time RT-PCR studies revealed that mRNAs of both iPLA₂ isozymes, that is, iPLA₂β and iPLA₂γ, were present in the noninflamed foot pad, and their levels did not change following carrageenan injection (Figure 2).

We then asked if BEL influences the induction of COX-2, mPGES-1, and PGIS, which are possibly involved in carrageenan-induced prostaglandin synthesis. COX-2 mRNA, mPGES-1 mRNA, and PGIS mRNA were increased by carrageenan injection though the increases did not reach the statistically significant level except for COX-2 mRNA and PGIS mRNA in carrageenan + BEL group (Figure 3). There was no significant effect of BEL on the COX-2 mRNA, mPGES-1 mRNA, or PGIS mRNA levels (Figure 3). We also examined the effects of BEL on carrageenan-induced proinflammatory cytokine mRNAs (Figure 4). Carrageenan significantly elevated the mRNA levels of IL1β and IL6. BEL slightly but significantly elevated carrageenan-induced IL1β mRNA and did not change carrageenan-induced IL6 mRNA. Therefore, BEL seemed to act solely on the enzyme activity of iPLA₂s resulting in suppression of prostaglandin levels in inflamed tissue.

Lastly, we studied the effects of PLA₂ inhibitors on carrageenan-induced thermal hyperalgesia. When carrageenan was injected with vehicle, foot withdrawal latency to radiant heat was reduced by approximately 70% compared to the preinjection level (at time point 0), indicating the induction of thermal hyperalgesia (Figure 5(a)). The thermal hyperalgesia was statistically significant throughout the observation period of 6 h ($N = 5$, $P < 0.005$). Carrageenan-induced thermal hyperalgesia was ameliorated by BEL by 44% at 1 h, 61% at 2 h, and 46% at 3 h after injection compared to vehicle-treated group. At these 3 time points, the difference between carrageenan + BEL group ($N = 6$) and carrageenan + vehicle group ($N = 5$) was statistically significant ($P = 0.026$, 0.014 , and 0.015 , resp.). On the other hand, AACOCF₃ did not influence the thermal hyperalgesia (Figure 5(a)). Injection of saline did not induce thermal hyperalgesia (Figure 5(b)). Both BEL and AACOCF₃ did not show significant effect in saline-injected foot pad.

4. Discussion

PGE₂ and PGI₂ are known to sensitize nociceptors and develop hyperalgesia during inflammation [1, 2]. However, which isoform of PLA₂ is involved in the synthesis of these prostaglandins in inflammatory tissues was unclear. In the present study, we showed that BEL, a potent inhibitor of iPLA₂, lowered these prostaglandins by approximately 50% in rat foot pads that were inflamed with carrageenan. The inhibitor also halved carrageenan-induced thermal hyperalgesia during the first 3 h after injection. We confirmed that mRNAs of iPLA₂β and iPLA₂γ were constitutively expressed in the rat foot pad. This result is in line with the study by Gilroy et al. [10], who demonstrated that BEL reduced PGE₂ content in the cell-free inflammatory exudates of the pleural cavity 3 h after carrageenan injection.

It should be noted that BEL is also a potent inhibitor of phosphatidic acid phosphohydrolase. Grkovich et al.




FIGURE 1: Contents of PGE₂ (a) and 6-keto-PGF_{1α} (b) in rat hind paw. Carrageenan (Car) injection (filled bars) significantly elevated both prostaglandin levels compared to saline (Sal) injection (open bars) in vehicle-, BEL-, and AACOCF₃- (AACO-) treated groups ($P = 0.0002$ – 0.014 , t -test, $N = 4$ in each group). BEL but not AACOCF₃ significantly suppressed carrageenan-induced increases in PGE₂ (a) and 6-keto-PGF_{1α} (b) compared to vehicle ($P = 0.009$ for PGE₂ and $P = 0.017$ for 6-keto-PGF_{1α}, multiple t -tests with Bonferroni correction, 2 comparisons among 3 groups; vehicle versus BEL and vehicle versus AACOCF₃). Asterisks indicate the statistical significance of the difference between vehicle + carrageenan group and BEL + carrageenan group.




FIGURE 2: Levels of mRNA of iPLA₂β and iPLA₂γ relative to that of an internal control gene (GAPDH) in rat hind paw. Their relative levels were not influenced by carrageenan-induced inflammation. Open bars and filled bars represent results from saline (Sal)-injected group and carrageenan (Car)-injected group, respectively. $N = 4$ in each group.

[13] reported that BEL suppressed COX-2 expression in LPS-activated macrophages through the inhibition of phosphatidic acid phosphohydrolase-1. Therefore, we wondered if BEL might have reduced prostaglandin levels by suppressing COX-2 induction. However, in the present study, carrageenan-induced COX-2 mRNA was not affected by BEL. This was also the case for mRNAs of mPGES-1 and PGIS, the final enzymes in PGE₂ and PGI₂ synthesis, respectively.

In line with these results, BEL did not reduce carrageenan-induced proinflammatory cytokines, which are strong inducers of COX-2 and other enzymes in the arachidonic acid cascade. These results strongly suggest that BEL did not significantly suppress inflammation but inhibited iPLA₂ enzyme activity to reduce carrageenan-induced PGE₂ and PGI₂ synthesis and, consequently, thermal hyperalgesia. Therefore, we conclude that iPLA₂ is responsible for the synthesis of prostaglandins in carrageenan-induced tissue inflammation.

Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for the treatment of inflammatory pain. NSAIDs potently inhibit COX but do not suppress the supply of its substrate, that is, arachidonic acid. Thus, free arachidonic acid may enter lipoxygenase or epoxygenase pathways to be various potent eicosanoids such as leukotrienes. This may result in side effects of NSAIDs. On the other hand, since inhibitors of PLA₂, such as BEL, reduce the supply of free arachidonic acid, PLA₂ inhibitors may be more ideal in the treatment of symptoms induced by eicosanoids than NSAIDs.

The inhibition of prostaglandin synthesis by BEL was partial—approximately 50% of the control (vehicle alone). This fact suggests that other PLA₂ isoforms, that is, cPLA₂ or sPLA₂s, also participated in carrageenan-induced prostaglandin synthesis. Traditionally, cPLA₂ has been considered the major PLA₂ that cleaves arachidonic acid from the sn-2 position of membrane phospholipids during inflammation. In the present study injection of AACOCF₃, a cPLA₂ inhibitor, into the foot pad neither reduced PGE₂ and PGI₂ nor suppressed thermal hyperalgesia, suggesting that cPLA₂ does not play a significant role in these responses. This result is consistent with those of two previous studies, the first of which by Gilroy et al. [10] showed no effect of AACOCF₃




FIGURE 3: Relative expression of COX-2 mRNA (a), mPGES-1 mRNA (b), and PGIS mRNA (c) in rat hind paw. Carrageenan (Car) injection (filled bars) elevated COX-2 mRNA and mPGES-1 mRNA levels compared to saline (Sal) injection (open bars) though the elevations were not statistically significant by *t*-test except for COX-2 and PGIS in BEL-treated groups. BEL did not significantly influence COX-2 mRNA, mPGES-1 mRNA, or PGIS mRNA levels.




FIGURE 4: Relative expression of IL1 β mRNA (a) and IL6 mRNA (b) in rat hind paw. Carrageenan (Car) injection (filled bars) significantly elevated IL1 β mRNA and IL6 mRNA levels compared to saline (Sal) injection (open bars) ($P < 0.05$). BEL slightly but significantly elevated carrageenan-induced IL1 β mRNA ($P < 0.05$) and did not affect carrageenan-induced IL6 mRNA.




FIGURE 5: Paw-withdrawal latencies to radiant heat. (a) The latencies were reduced by approximately 70% after carrageenan (Car) injection in vehicle-treated group. The reduction was statistically significant throughout the observation period of 6 h ($N = 5$, $P < 0.005$, multiple t -tests with Bonferroni correction, 6 comparisons among 7 groups; time point 0 versus time points 1–6). Treatment with BEL but not with AACOCF₃ prolonged the latencies at 1 h, 2 h, and 3 h after injection. At these time points, the effect of BEL was statistically significant ($P = 0.026$, 0.014, and 0.015, resp., multiple t -tests with Bonferroni correction, 2 comparisons among 3 groups; vehicle versus BEL and vehicle versus AACOCF₃ in each time point). Asterisks indicate the statistical significance of the difference between vehicle + carrageenan group and BEL + carrageenan group. (b) Saline (Sal) injection had little effect on paw-withdrawal latencies. PLA₂ inhibitors did not influence the latencies in saline-injected groups.

on the PGE₂ content of cell-free inflammatory exudates of the pleural cavity 3 h after carrageenan injection. The second study by Lucas et al. [11] reported that intraplantar injection of AACOCF₃ did not suppress carrageenan-induced thermal hyperalgesia even with a dose approximately 20 times higher than that used in the present study. On the other hand, it is reported that a new type of cPLA₂ inhibitor reduced carrageenan-induced PGE₂ production in the rat air pouch [14]. The reason for the discrepancy is unclear at present, and we cannot completely exclude the possibility that cPLA₂ is partly involved in PGE₂ and PGI₂ production in inflammatory tissues.

PGE₂ and possibly PGI₂ augment nociceptive responses by acting in multiple sites along the pain processing neural pathway. In each site, distinct isoforms of PLA₂ seem to be involved in prostaglandin synthesis. In the peripheral inflammatory site, these prostaglandins are produced by the action of iPLA₂ and sensitize nociceptors, as shown in this study. In the spinal cord, PGE₂ is produced in response to nociceptive neural inputs from the primary sensory neurons and possibly enhances the pain signal transmission [15]. In this site, cPLA₂ and sPLA₂ but not iPLA₂ are reported to play major roles in PGE₂ synthesis and hyperalgesic response [11, 16]. Furthermore, in the spinal cord and brain, peripheral inflammation induces prostaglandin synthesis through the action of circulating inflammatory cytokines such as interleukin-6 [17]. This is evidenced by an elevation of PGE₂ in the cerebrospinal fluid and induction of COX-2 in endothelial cells throughout the brain and spinal cord after intraplantar injection of carrageenan [18]. Antiserum to interleukin-6 suppressed these responses [17]. However, little is known

about which isoform of PLA₂ is activated upstream of COX-2. Further studies are necessary to thoroughly determine which PLA₂ isoforms are involved in prostaglandin synthesis in the central nervous system under inflammatory conditions.

5. Conclusion

The present study has indicated the importance of iPLA₂ in prostaglandin synthesis at the inflammatory site and suggested that iPLA₂ is a possible target for the treatment of inflammatory hyperalgesia.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

The authors thank Dr. Aiko Hori and Ms. Tomoko Yamamoto for helping in the measurements of prostaglandins. This work was supported by KAKENHI (25460322 and 24592354).

References

- [1] S. H. Ferreira, "Peripheral analgesia: mechanism of the analgesic action of aspirin like drugs and opiate-antagonists," *British Journal of Clinical Pharmacology*, vol. 10, no. 2, pp. 237S–245S, 1980.
- [2] H. Meves, "The action of prostaglandins on ion channels," *Current Neuropharmacology*, vol. 4, no. 1, pp. 41–57, 2006.

- [3] T. Moriyama, T. Higashi, K. Togashi et al., "Sensitization of TRPV1 by EP1 and IP reveals peripheral nociceptive mechanism of prostaglandins," *Molecular Pain*, vol. 1, article 3, 2005.
- [4] S. Materazzi, R. Nassini, E. Andrè et al., "Cox-dependent fatty acid metabolites cause pain through activation of the irritant receptor TRPA1," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 33, pp. 12045–12050, 2008.
- [5] W. L. Smith, L. J. Marnett, and D. L. Dewitt, "Prostaglandin and thromboxane biosynthesis," *Pharmacology and Therapeutics*, vol. 49, no. 3, pp. 153–179, 1991.
- [6] D. Kamei, K. Yamakawa, Y. Takegoshi et al., "Reduced pain hypersensitivity and inflammation in mice lacking microsomal prostaglandin E synthase-1," *The Journal of Biological Chemistry*, vol. 279, no. 32, pp. 33684–33695, 2004.
- [7] K. Seibert, Y. Zhang, K. Leahy et al., "Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 91, no. 25, pp. 12013–12017, 1994.
- [8] I. Kudo and M. Murakami, "Phospholipase A₂ enzymes," *Prostaglandins & Other Lipid Mediators*, vol. 68-69, pp. 3–58, 2002.
- [9] R. H. Schaloske and E. A. Dennis, "The phospholipase A₂ superfamily and its group numbering system," *Biochimica et Biophysica Acta—Molecular and Cell Biology of Lipids*, vol. 1761, no. 11, pp. 1246–1259, 2006.
- [10] D. W. Gilroy, J. Newson, P. Sawmynaden, D. A. Willoughby, and J. D. Croxtall, "A novel role for phospholipase A₂ isoforms in the checkpoint control of acute inflammation," *The FASEB Journal*, vol. 18, no. 3, pp. 489–498, 2004.
- [11] K. K. Lucas, C. I. Svensson, X. Y. Hua, T. L. Yaksh, and E. A. Dennis, "Spinal phospholipase A₂ in inflammatory hyperalgesia: role of group IVA cPLA 2," *British Journal of Pharmacology*, vol. 144, no. 7, pp. 940–952, 2005.
- [12] D. M. Dirig, A. Salami, M. L. Rathbun, G. T. Ozaki, and T. L. Yaksh, "Characterization of variables defining hindpaw withdrawal latency evoked by radiant thermal stimuli," *Journal of Neuroscience Methods*, vol. 76, no. 2, pp. 183–191, 1997.
- [13] A. Grkovich, C. A. Johnson, M. W. Buczynski, and E. A. Dennis, "Lipopolysaccharide-induced cyclooxygenase-2 expression in human U937 macrophages is phosphatidic acid phosphohydrolase-1-dependent," *The Journal of Biological Chemistry*, vol. 281, no. 44, pp. 32978–32987, 2006.
- [14] J. C. McKew, K. L. Lee, M. W. Shen, P. Thakker, J. C. McKew, and M. Shen, "Indole cytosolic phospholipase A₂ alpha inhibitors: discovery and in vitro and in vivo characterization of 4-3-[5-chloro-2-(2-[(3,4-dichlorobenzyl)sulfonyl]aminoethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propylbenzoic acid, efipladib," *Journal of Medicinal Chemistry*, vol. 51, no. 12, pp. 3388–3413, 2008.
- [15] T. L. Yaksh, X.-Y. Hua, I. Kalcheva, N. Nozaki-Taguchi, and M. Marsala, "The spinal biology in humans and animals of pain states generated by persistent small afferent input," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 96, no. 14, pp. 7680–7686, 1999.
- [16] C. I. Svensson, K. K. Lucas, X. Y. Hua, H. C. Powell, E. A. Dennis, and T. L. Yaksh, "Spinal phospholipase A₂ in inflammatory hyperalgesia: role of the small, secretory phospholipase A₂," *Neuroscience*, vol. 133, no. 2, pp. 543–553, 2005.
- [17] Y. Oka, T. Ibuki, K. Matsumura et al., "Interleukin-6 is a candidate molecule that transmits inflammatory information to the CNS," *Neuroscience*, vol. 145, no. 2, pp. 530–538, 2007.
- [18] T. Ibuki, K. Matsumura, Y. Yamazaki, T. Nozaki, Y. Tanaka, and S. Kobayashi, "Cyclooxygenase-2 is induced in the endothelial cells throughout the central nervous system during carrageenan-induced hind paw inflammation; its possible role in hyperalgesia," *Journal of Neurochemistry*, vol. 86, no. 2, pp. 318–328, 2003.